Dacarfen 100 Injection contains Dacarbazine 100mg, a widely used alkylating chemotherapy agent primarily indicated for Hodgkin’s lymphoma, metastatic melanoma, and various soft tissue sarcomas. Its proven cytotoxic action helps inhibit cancer cell growth and is frequently included in established oncology regimens such as ABVD therapy for Hodgkin’s disease.
This formulation offers reliable pharmacological performance with consistent absorption and therapeutic delivery, making it suitable for both inpatient chemotherapy and oncology day-care infusion settings. Its role across multiple cancer indications ensures strong medical relevance in cancer treatment protocols.
For wholesalers, oncology suppliers, and hospital distributors, Dacarfen 100 Injection is a high-rotation chemotherapy product, regularly required in oncology OPDs, cancer institutes, specialty clinics, and multispecialty hospitals. As Hodgkin’s lymphoma treatments run over several cycles, the product ensures predictable reorder demand.
Adding Dacarfen 100 to your oncology portfolio reinforces your cancer-care and chemotherapy segment, enabling supply opportunities in government hospitals, private oncology chains, institutional procurement, export consignments, and third-party manufacturing partnerships. Its essential role in hematology and oncology makes it a profitable addition to any pharmaceutical distributor’s catalogue.